Leukemia Research
Volume 33, Issue 11 , Pages 1450-1451 , November 2009

Are there new clinical parameters useful to predict response in chronic myeloid leukemia in the imatinib era?

  • Massimo Breccia

      Affiliations

    • Corresponding Author InformationCorresponding author at: Department of Human Biotechnologies and Hematology, Via Benevento 6, 00161 Rome, Italy. Tel.: +39 06 857951; fax: +39 06 44241984.
    • ,
  • Giuliana Alimena

Received 15 June 2009

References 

  1. Faderl S, Talpaz M, Estrov Z, Kantarjian H. Chronic myelogenous leukemia: biology and therapy. Ann Intern Med. 1999;131:207–219
  2. Goldman JM, Melo JV. Chronic myeloid leukemia—advances in biology and new approaches to treatment. N Engl J Med. 2003;349:1451–1464
  3. Druker BJ. Translation of the Philadelphia chromosome into therapy for CML. Blood. 2008;112:4808–4817
  4. Sattler M, Griffin JD. Molecular mechanisms of transformation by the BCR-ABL oncogene. Semin Hematol. 2003;40:4–10
  5. Baccarani M, Saglio G, Goldman J, Hochhaus A, Simonsson B, Appelbaum F, et al. European Leukemia Net. Evolving concepts in the management of chronic myeloid leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet. Blood. 2006;108:1809–1820
  6. Hughes TP, Kaeda J, Branford S, Rudzki Z, Hochhaus A, Hensley ML, et al. Frequency of major molecular responses to imatinib or interferon alfa plus cytarabine in newly diagnosed chronic myeloid leukemia. New Engl J Med. 2003;349:1423–1432
  7. Simonsson B, on behalf of the IRIS study group. Beneficial effects of cytogenetic and molecular response on long term outcome in patients with newly diagnosed chronic myeloid leukaemia in chronic phase (CML-CP) treated with imatinib: update from the IRIS study. Blood 2005;106:52a
  8. Quintas-Cardama A, Kantarjian H, Jones D, Shan J, Borthakur G, Thomas D, et al. Delayed achievement of cytogenetic and molecular response is associated with increased risk of progression among patients with chronic myelogenous leukemia in early chronic phase receiving high-dose or standard-dose imatinib therapy. Blood 2009;Apr 15 [Epub ahead of print].
  9. Wang L, Pearson K, Ferguson JE, Clark RE. The early molecular response to imatinib predicts cytogenetic and clinical outcome in chronic myeloid leukaemia. Br J Haematol. 2003;120:990–999
  10. Merx K, Müller MC, Kreil S, Lahaye T, Paschka P, Schoch C, et al. Early reduction of BCR-ABL mRNA transcript levels predicts cytogenetic response in chronic phase CML patients treated with imatinib after failure of interferon alpha. Leukemia. 2002;16:1579–1583
  11. Paschka P, Müller MC, Merx K, Kreil S, Schoch C, Lahaye T, et al. Molecular monitoring of response to imatinib (Glivec) in CML patients pretreated with interferon alpha. Low levels of residual disease are associated with continuous remission. Leukemia. 2003;17:1687–1694
  12. Hughes TP, Hochhaus A, Branford S, Muller MC, Foroni L, Druker BJ, et al. Reduction of BCR-ABL transcript levels at 6, 12, and 18 months (mo) correlates with long-term outcomes on imatinib (IM) at 72 Mo: an analysis from the International Randomized Study of Interferon versus STI571 (IRIS) in patients (pts) with chronic phase chronic myeloid leukemia (CML-CP). Blood. 2008;112:abstr 334
  13. Picard S, Titier K, Etienne G, Teilhet E, Ducint D, Bernard MA, et al. Trough imatinib plasma levels are associated with both cytogenetic and molecular responses to standard-dose imatinib in chronic myeloid leukemia. Blood. 2007;109:3496–3499
  14. Cortes JE, Egorin MJ, Guilhot F, Molimard M, Mahon FX. Pharmacokinetic/pharmacodynamic correlation and blood-level testing in imatinib therapy for chronic myeloid leukemia. Leukemia 2009;Apr 30 [Epub ahead of print].
  15. Song MK, Chung JS, Seol YM, Shin HJ, Choi YJ, Cho GJ, et al. Mean cell volume can be an early predictor for the cytogenetic response of chronic myeloid leukaemia patients treated with imatinib?. Leuk Res. 2009;33:1459–1462

PII: S0145-2126(09)00318-X

doi: 10.1016/j.leukres.2009.06.022

Leukemia Research
Volume 33, Issue 11 , Pages 1450-1451 , November 2009

Article Tools